2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.

Bernardo Leon Rapoport Jørn HerrstedtRebecca Clark SnowVenkatraman RadhakrishnanMitsue SaitoRudolph M NavariTeresa Smit

Published in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2023)

receptor antagonist plus dexamethasone plus aprepitant plus olanzapine. For patients experiencing breakthrough nausea and vomiting, the available evidence suggests using a single dose of olanzapine daily for 3 days.

Keyphrases

high dose
chemotherapy induced
end stage renal disease
low dose
ejection fraction
chronic kidney disease
newly diagnosed
locally advanced
prognostic factors
clinical practice
stem cell transplantation
peritoneal dialysis
squamous cell carcinoma
physical activity
patient reported outcomes
radiation therapy